Full history for every metric is available with a Kvantra account
Agile Therapeutics, Inc. (AGRX)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 1 | 4 | 11 | 20 | 22 |
| Operating profit | $m | -20 | -14 | |||||
| Net profit | $m | -20 | -18 | -55 | -77 | -25 | -14 | -16 |
| EPS reported | $ | -6.71 | -3.23 | |||||
| Operating cashflow per share | $ | -4.44 | -4.44 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -4.44 | -4.44 | |||||
| Free cash flow | $m | -10 | -2 | |||||
| Net debt | $m | -1 | -3 | |||||
| Book value equity | $m | -16 | -22 | |||||
| Book value per share | $ | -7.57 | -3.20 | |||||
| Number of shares | m | 2.16 | 6.86 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.26 | -0.48 | |||||
| P/S LTM | x | 0.21 | 0.48 | |||||
| P/FCF LTM | x | -0.44 | -6.11 | |||||
| EV/EBITDA LTM | x | -0.30 | -1.35 | |||||
| EV/Sales LTM | x | 0.19 | 0.35 | |||||
| Earnings Yield LTM | % | -343.94% | -444.17% | |||||
| FCF Yield | % | -227.72% | -16.36% | |||||
| Quality | ||||||||
| ROE | % | 88.64% | 132.32% | |||||
| ROIC | % | 235.31% | 235.31% | |||||
| Operating margin | % | -101.49% | -101.49% | |||||
| Gross margin | % | 54.18% | 54.18% | |||||
| FCF/Sales | % | -48.88% | -48.88% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +80.02% | +32.21% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.41 | -5.90 | |||||
| Net Debt/EBITDA | x | 0.03 | 0.03 | |||||
| EBIT/Net interest | x | -14.01 | -14.01 | |||||
| Net debt/market cap | % | -20.23% | -27.32% | |||||
| Net debt/Equity | x | 0.05 | 0.13 | |||||
| Gross debt/equity | x | -0.13 | -0.01 | |||||
Company overview
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Agile Therapeutics, Inc. (AGRX)
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free